中国医学创新Issue(4)：25-26,2.DOI:10.3969/j.issn.1674-4985.2013.04.013
替吉奥联合奥沙利铂治疗晚期胃癌临床评价
Clinical Evaluation of the Combination of S-1 and Oxaliplatin in the Treatment of Patients with Advanced Gastric Cancer
刘涛 1刘哲 2张剑3
作者信息
- 1. 江苏省徐州市第六人民医院 江苏 徐州 221002
- 2. 山东省郓城县人民医院
- 3. 复旦大学附属肿瘤医院
- 折叠
摘要
Abstract
Objective:To evaluate the efficacy and toxicity of the combination regimen of S1 and oxaliplatin(SOX)in the treatment of patients with advanced gastric cancer.Method:A total of 38 patients with advanced gastric cancer were treated with SOX regimen.S-1 was administered orally, 40 mg/(m2·d),bid,with a schedule of 14 days on and 7 days off,while oxaliplatin was administered i.v.(130 mg/m2)on day 1.The regimen was repeated every 21 days.The efficacies and toxicities were evaluated with RECIST 1.1 and CTC-AE 4.0.Result:Of the 38 evaluable patients,there were 2(5.26%)complete remission(CR),12(31.58%)partial remission(PR),15(39.47%)stable disease(SD),and 9(23.68%)progression disease(PD).The overall response rate and the disease control rate(DCR)was 36.84% and 76.31%,respectively.The time to progression(TTP)was 7.9 months.The median survival time(MST)was 10.2 months.The major toxicities included myelosuppression,gastrointestinal reaction and peripheral neurotoxicity.Conclusion:The combination of S-1 and oxaliplatin is effective and tolerable in the treatment of patients with advanced gastric cancer and is worthy of further evaluation.关键词
晚期胃癌/替吉奥/奥沙利铂/化疗Key words
Advanced gastric cancer/S-1/Oxaliplatin/Chemotherapy引用本文复制引用
刘涛,刘哲,张剑..替吉奥联合奥沙利铂治疗晚期胃癌临床评价[J].中国医学创新,2013,(4):25-26,2.
